Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Holding RAPP?
Track your performance easily
RAPP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.55 - $29.74
Previous Close$18.77
Volume142.07K
Average Volume (3M)151.30K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$320.66M
Total Debt (Recent Filing)$1.65M
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Nov 07, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,576,457
10 Day Avg. Volume145,514
30 Day Avg. Volume151,301
Standard Deviation0.11
R-Squared0.60
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-17.38
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$38.50Price Target Upside105.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Rapport Therapeutics, Inc. News
PremiumCompany Announcements
Rapport Therapeutics Reports Q3 Financials and Strategic UpdatesBulls Say, Bears Say
Bulls Say
Clinical Research And Biomarker DevelopmentData supports the use of a novel efficacy biomarker in the ongoing Phase II epilepsy study of RAP-219, which can predict Phase II/III success.
Market Potential And ExpansionBeyond epilepsy, Rapport is also developing RAP-219 for neuropathic pain and acute mania associated with bipolar disorder, representing significant upside potential.
Phase II Study And Stock OpportunityPhase II epilepsy study now enrolling suggests a potential $1B+ opportunity with a 25-35% stock upside.
Bears Say
Clinical Trial ChallengesThe FDA placed a clinical hold on the IND for the Ph. IIa trial of RAP-219 in diabetic peripheral neuropathic pain.
Regulatory IssuesIND application for Phase IIa trial of RAP-219 in diabetic peripheral neuropathic pain placed on clinical hold by the FDA.
Study Design ConcernsThe Phase IIa study is open-label and will enroll just 20 patients, which may limit the robustness of efficacy data.
---
Ownership Overview
Currently, No data available
---
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $16.55 and its highest was $29.74 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2024 which is 45 days ago.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 08, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$1.1.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -$0.56.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 36,576,458 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$1.7 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went up 2.868%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Among the largest hedge funds holding Rapport Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds Rapport Therapeutics, Inc.’s shares valued at 15M.
---
Rapport Therapeutics, Inc. Stock Smart Score
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
---
RAPP Stock 12 Month Forecast
Average Price Target
$38.50
▲(105.11% Upside)
Technical Analysis
Best Analysts Covering RAPP
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-2.53%
assigned a buy rating 15 days ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -2.53% per trade.
---